8/15/2023 0 Comments Venture capital firms topMedicxi Growth 1 will invest in European life sciences companies with compounds in Phase II or beyond with potential to be licensed. “Success stories like Neuravi and Rotation Medical from the first LSP Health Economics Fund are great examples,” stated Managing Partner Rudy Dekeyser after the launch.įrom London, Medicxi launched a $300M (about €240M) fund in June that counts with money from Google’s Verily, Novartis, and the European Investment Fund. LSP’s fund will invest in around 15 companies across Europe and the US whose products are close to the market, which the VC expects to turn into good returns. Called LSP Health Economics Fund 2, it is set to invest €280M - part of it coming from the European Investment Fund - in companies working in medical devices, diagnostics and digital health. “We have invested in all economic crises or stock market downturns in the last 15 years and always managed to distribute money to our LPs,” EdRip partner Raphaël Wisniewski recently told EP Vantage.ĮdRip’s new fund has already made three investments, including Berlin-based Complexa, working in the field of inflammatory disease and Erytech, a Parisian biotech using red blood cells to treat cancer.īased in Amsterdam, Life Sciences Partners (LSP) is boosting its investment on medical technology with a new fund launched in December. About two thirds will be destined to biotech and the rest to medtech companies. The new fund, called BioDiscovery 5, is set to invest in preclinical and early clinical stage companies over a four to five-year period, with 70% committed to European companies. Paris-based Edmond de Rothschild (EdRip) tops our list this year with the closing of a €345M fund on February. So I’ve put together a list of the 10 biotech venture capital firms in Europe that have been most active in the past year and are likely to protagonize some of the biggest deals in European biotech in 2018. The list is ordered according to the VCs recent investment activity and the size of their most recent closing of a biotech fund. Sounds easy? Investing right can be as difficult as convincing investors that your company is worth funding. They give you a few millions, and, if your company is successful, they will get a few more in return. That’s what venture capital firms are for. And given the long time it takes to fully develop and commercialize a biotech product, these companies need millionaire funding. They need it to develop the science, run clinical trials, manufacture its products and pay the salaries of their motivated workers. But there is a common challenge to all biotech companies trying to make the world a bit of a better place: money. Who’s funding the biotech industry in Europe? I’ve gathered a list of some of the most active European biotech venture capital firms that will be setting the pace of the industry this year.īiotech can do great things, from curing deadly diseases to helping make the plastics industry more sustainable.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |